Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fosinopril sodium
Drug ID BADD_D00968
Description Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Indications and Usage For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Marketing Status Prescription; Discontinued
ATC Code C09AA09
DrugBank ID DB00492
KEGG ID D00622
MeSH ID D017328
PubChem ID 23666105
TTD Drug ID D0X8KY
NDC Product Code 50268-329; 70934-632; 16571-770; 65862-471; 50090-4743; 16571-771; 65862-393; 65862-473; 63629-6994; 76282-201; 43547-387; 65862-472; 71335-1115; 76282-200; 50268-328; 43547-388; 16571-772; 76282-202; 65977-0004
Synonyms Fosinopril | Fosenopril | Fosinil | Fositens | Fosinopril Sodium | Sodium, Fosinopril | Fosinopril, (1(S*(R*)),2 alpha,4 beta)-Isomer | Fosinopril, (1(S*(R*)),2 alpha,4 alpha)-(D-Pro)-Isomer | Tenso Stop | Tensocardil | Fozitec | Hiperlex | Monopril | Fosinorm | Newace | Staril | SQ-28,555 | SQ 28,555 | SQ28,555 | SQ-28555 | SQ 28555 | SQ28555 | Dynacil | Fosinopril, (1(S*(S*)),2 alpha,4 beta)-Isomer
Chemical Information
Molecular Formula C30H45NNaO7P
CAS Registry Number 88889-14-9
SMILES CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2CC(CC2C(=O)[O-])C3CCCCC3.[Na+]
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Agranulocytosis01.02.03.001--Not Available
Anaemia01.03.02.001--
Anaphylactoid reaction10.01.07.003; 24.06.03.007--Not Available
Angioedema10.01.05.009; 23.04.01.001--Not Available
Arrhythmia02.03.02.001--Not Available
Arrhythmia supraventricular02.03.03.001--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Asthenia08.01.01.001--Not Available
Blood bilirubin increased13.03.01.008--
Blood creatine increased13.13.01.001--Not Available
Blood lactate dehydrogenase increased13.04.02.002--
Blood urea increased13.13.01.006--Not Available
Bradycardia02.03.02.002--Not Available
Bronchospasm10.01.03.012; 22.03.01.004--
Cardiac arrest02.03.04.001--
Cardio-respiratory arrest02.03.04.002; 22.02.06.007--Not Available
Cerebral infarction17.08.01.004; 24.04.06.002--Not Available
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Chest pain02.02.02.011; 08.01.08.002; 22.02.08.003--Not Available
Conduction disorder02.03.01.008--
Confusional state17.02.03.005; 19.13.01.001--
Constipation07.02.02.001--
Cough22.02.03.001--
Depression19.15.01.001--
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Diarrhoea07.02.01.001--
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.007--
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages